Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

at (ITT) population from the two randomized Phase 3 studies. Researchers used fixed-effects meta-analysis and Cox regression models to complete the analysis, fixing the time of the 8-12 day primary end of therapy assessment utilized in the clinical trials at 12 days.

Additional Study Results

In the two Phase 3 studies, DIFICID achieved clinical cure rates at the end of treatment that were non-inferior to oral vancomycin and lower recurrence rates that were statistically significant. In the ITT analysis, the superior reduction in persistent diarrhea or death seen at day 12 for DIFICID (p=0.037) was driven by 7 deaths among DIFICID-treated patients (1.2%) compared to 17 (2.9%) deaths among patients who received vancomycin (exact p=0.06). The overall analysis demonstrated a 40% reduction in persistent diarrhea, disease recurrence or death (all causes) compared to vancomycin through day 40 of the study (95% CI: 26-51%; p<0.0001).

Results of the ITT combined analysis also show that randomization to DIFICID in the Phase 3 clinical studies reduced the risk of persistent diarrhea, recurrence or death by 52% (95% CI: 37-63%; p<0.0001), even after adjusting for other factors. Persistent diarrhea or death in the first 12 days following initiation of treatment was most strongly predicted by previous anti-CDAD antibiotic use in the 24 hours prior to randomization (p=0.0001) and low baseline eosinophils (p=0.007) and/or albumin (p<0.0001) at randomization. Patients with CDAD in the three months prior to entering the study had a 68% higher risk of recurrence or death during study days 13-40. Through 40 days, there was no evidence that the benefits of DIFICID over vancomycin varied according to disease severity, prior history of CDAD, previous anti-CDAD antibiotics, inpatient versus outpatient, patient age, baseline albumin or baseline creatinine levels.

About CDAD

Clostridium difficile-associated diarrhea (CDAD) ha
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... CARLSBAD, Calif. , July 10, 2014 /PRNewswire/ ... products and services, has launched the FreeRunner™ knee ... runners, who suffer from patella mal-tracking return to ... anatomy differently than other braces, providing support when ... move normally when they don,t. Patellofemoral ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... ROCHESTER, N.Y., Sept. 8 VirtualScopics, Inc. (Nasdaq: ... for clinical trials, announced today that Ms. Molly Henderson, ... presenting a corporate overview at the Rodman & Renshaw ... City. Ms. Henderson,s presentation will be on Tuesday, September ...
... N.J., Sept. 8 Today every major pharmaceutical industry ... the future of pharma.  In an unprecedented move, they,re ... the big names in pharma.  All in one place. ... at the Pharma CI Conference & Exhibition at the ...
Cached Medicine Technology:VirtualScopics to Present at the Upcoming Rodman & Renshaw Annual Global Investment Conference 2Pharmaceutical Industry Insiders, VIPs All Coming Together for Future of Pharma Market, Pharmaceutical Competitive Intelligence 2
(Date:7/10/2014)... (PRWEB) July 11, 2014 The Capital ... has performed the first procedure in a clinical trial ... inserted in the leg. , During the procedure, done ... Veznedaroglu, an endovascular neurosurgeon, threaded a tiny catheter through ... the body and neck and into the brain. Once ...
(Date:7/10/2014)... acids had healthier joints than those fed diets high ... to Duke Medicine researchers. , The findings, published in ... on July 11, 2014, suggest that unhealthy dietary fats ... osteoarthritis. , "Our results suggest that dietary factors play ... link between obesity and osteoarthritis," said Farshid Guilak, Ph.D., ...
(Date:7/10/2014)... More than 200 experts on aggression, ... street violence, will attend the 21st World Meeting of ... (ISRA) at the Loews Atlanta Hotel, July 15-19. , ... world meeting, which is held every other year on ... together leading scholars from more than 20 different countries, ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Fatigue, ... for an increasing number of accidents in the ... Safety Reboot. The articles highlight safety issues that ... 317 million accidents occur on the job annually, ... features continue to explore "preventable workplace accidents." , ...
(Date:7/10/2014)... Wisconsin (PRWEB) July 10, 2014 Ticketability.com has ... Tour,” and now Paul McCartney tickets for San Diego are ... in San Diego since 1976, and the newly added September ... California fans. , Click Here to view the ... tickets for Petco Park will become available to the general ...
Breaking Medicine News(10 mins):Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 2Health News:Safety Reboot Magazine Focuses on: Why Extended Hours is Dangerous in the Workplace; Why Custodial Work Can be Dangerous; and Improving Safety for Roofers 3Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2
... Every Birth is Safe for Pregnant Women , ... , , ... ... NEW YORK , March 22 ...
... ... ... ... WASHINGTON , March 22 With the passage of the historic health care legislation, the National Medical ...
... has been a major increase in the incidence of ... differing opinions as to why this is (environment, vaccines, ... are still many children who have autistic traits that ... the support they need through educational or health services. ...
... Cycling jerseys and ... ... announced today the addition of a durable, visible and practical backpack for cyclists with ... to help remind motorists to give cyclists at least 3 feet clearance when passing them from ...
... and Services for the Aging, on passage of Health Reform Legislation: , ... , , ... ... "We commend the U.S. ...
... Capital 2010 High Yield Bond and Syndicated Loan Conference in Phoenix, Ariz. , on March 24-26, 2010 . , ... , , ... ... HealthSouth Senior Vice ...
Cached Medicine News:Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 2Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 3Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 4Health News:Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care 5Health News:National Medical Association, Health System Reform - From Legislation to Implementation 2Health News:National Medical Association, Health System Reform - From Legislation to Implementation 3Health News:New Backpack for Cyclists Sends a Polite Message to Motorists: '3 Feet Please' 2Health News:New Backpack for Cyclists Sends a Polite Message to Motorists: '3 Feet Please' 3Health News:AAHSA Statement on Passage of Health Reform Legislation 2Health News:HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference 2Health News:HealthSouth To Present at Barclays Capital 2010 High Yield Bond and Syndicated Loan Conference 3
Part of the GraFix® Cruciate Reconstruction System, which is designed to facilitate arthroscopic anterior cruciate ligament reconstructions....
... Sgarlato Lab's bring a new standard in the ... by Sgarlato Labs. Made of medical grade silicone, ... patient with a high level of flexibility while ... Rods are available in varying stiffnesses. Lengths are ...
... Implant (KGTI) system offers the latest technology ... MPJ. The implant system is anatomically designed ... ,The KGTI is the most advanced reconstructive ... on the market today. The system consists ...
... has been approved for use as an ... seizures in adults and adolescents over 12 ... that are refractory to antiepileptic medications. This ... controlled, clinical trials. Efficacy, measured as median ...
Medicine Products: